

Resource Summary Report

Generated by [dkNET](#) on Sep 1, 2026

SW837

RRID:CVCL_1729

Type: Cell Line

Proper Citation

RRID:CVCL_1729

Cell Line Information

URL: https://web.expasy.org/cellosaurus/CVCL_1729

Proper Citation: RRID:CVCL_1729

Description: Cell line SW837 is a Cancer cell line with a species of origin Homo sapiens (Human)

Sex: Male

Disease: Rectal adenocarcinoma

Defining Citation: [PMID:286328](#), [PMID:924690](#), [PMID:1000501](#), [PMID:6652615](#), [PMID:7104989](#), [PMID:7651727](#), [PMID:7824277](#), [PMID:8464898](#), [PMID:9715273](#), [PMID:10612807](#), [PMID:10737795](#), [PMID:11226274](#), [PMID:11687795](#), [PMID:12068308](#), [PMID:16418264](#), [PMID:18258742](#), [PMID:19927377](#), [PMID:20164919](#), [PMID:20215515](#), [PMID:20570890](#), [PMID:20606684](#), [PMID:22460905](#), [PMID:23272949](#), [PMID:23932154](#), [PMID:24755471](#), [PMID:24840470](#), [PMID:25485619](#), [PMID:25877200](#), [PMID:25926053](#), [PMID:25944804](#), [PMID:26589293](#), [PMID:27397505](#), [PMID:28196595](#), [PMID:28683746](#), [PMID:28854368](#), [PMID:29101300](#), [PMID:29444439](#), [PMID:30894373](#), [PMID:30971826](#), [PMID:31068700](#), [PMID:31395879](#), [PMID:31978347](#), [PMID:35839778](#)

Comments: Population: Caucasian., From: Scott and White Clinic; Temple; USA., Part of: TCGA-110-CL cell line panel., Part of: NCI RAS program mutant KRAS cell line panel., Part of: MD Anderson Cell Lines Project., Part of: FGFR genetic alteration cell panel (ATCC TCP-1034)., Part of: COSMIC cell lines project., Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE)., Part of: AstraZeneca Colorectal cell line (AZCL) panel.

Category: Cancer cell line

Organism: Homo sapiens (Human)

Name: SW837

Synonyms: SW-837, SW 837

Cross References: CLO:CLO_0009200, CLO:CLO_0009224, EFO:EFO_0002372, CLDB:cl4447, CLDB:cl4448, CLDB:cl4972, ArrayExpress:E-MTAB-38, ArrayExpress:E-MTAB-783, ArrayExpress:E-MTAB-2706, ArrayExpress:E-MTAB-2770, ArrayExpress:E-MTAB-3610, ATCC:CCL-235, BioGRID_ORCS_Cell_line:453, BioSample:SAMN03472312, BioSample:SAMN10987996, cancercellines:CVCL_1729, Cell_Model_Passport:SIDM00833, ChEMBL-Cells:ChEMBL3308361, ChEMBL-Targets:ChEMBL1075596, ColonAtlas:SW837, Cosmic:724852, Cosmic:873707, Cosmic:909755, Cosmic:948839, Cosmic:983734, Cosmic:985589, Cosmic:986021, Cosmic:995397, Cosmic:1043830, Cosmic:1122334, Cosmic:1132696, Cosmic:1184090, Cosmic:1310943, Cosmic:1312316, Cosmic:1374627, Cosmic:1479571, Cosmic:1676728, Cosmic:1708404, Cosmic:1805269, Cosmic:1995655, Cosmic:2302020, Cosmic:2664051, Cosmic:2760072, Cosmic:2800571, Cosmic-CLP:909755, DepMap:ACH-000421, ECACC:91031104, EGA:EGAS00001000610, EGA:EGAS00001000978, GDSC:909755, GEO:GSM817, GEO:GSM206554, GEO:GSM383864, GEO:GSM513925, GEO:GSM514315, GEO:GSM741265, GEO:GSM827281, GEO:GSM887679, GEO:GSM888771, GEO:GSM1006239, GEO:GSM1006240, GEO:GSM1006241, GEO:GSM1346893, GEO:GSM1374937, GEO:GSM1448195, GEO:GSM1670513, GEO:GSM2550018, IARC_TP53:95, IARC_TP53:23571, ICLC:HTL99021, IGRhCellID:SW837, JCRB:JCRB9115, LiGeA:CCLE_838, LINCS_LDP:LCL-1292, Lonza:1348, NCBI_Iran:C510, PharmacDB:SW837_1546_2019, PRIDE:PXD005235, PRIDE:PXD005354, PRIDE:PXD005355, PRIDE:PXD030304, Progenetix:CVCL_1729, PubChem_Cell_line:CVCL_1729, SKY/M-FISH/CGH:2849, Wikidata:Q54971210

ID: CVCL_1729

Record Creation Time: 20220427T221615+0000

Record Last Update: 20260830T000042+0000

Ratings and Alerts

No rating or validation information has been found for SW837.

No alerts have been found for SW837.

Data and Source Information

Source: [Cellosaurus](#)

Usage and Citation Metrics

We found 25 mentions in open access literature.

Listed below are recent publications. The full list is available at [dkNET](#) .

Beamon TC, et al. (2026) Beta-site Amyloid Precursor Protein Cleaving Enzyme 1 Overexpression Abrogates ST6GAL1 Mediated Rectal Cancer Chemoradiation

Resistance. *Cancer genomics & proteomics*, 23(4), 649.

Trekitkarnmongkol W, et al. (2026) RASH3D19 mediates RAS activation through a positive feedback loop in KRAS-mutant cancer. *Nature cell biology*, 28(1), 197.

Zhu G, et al. (2026) Accumulated sotorasib-bound KRASG12C reactivates the MAPK pathway and drives sotorasib resistance via the DHX9-RAC1-PAK1 axis. *Cell reports*, 45(5), 117338.

Buzo K, et al. (2026) WEE1 kinase inhibition to overcome acquired resistance to targeted therapies in colorectal cancer. *EMBO molecular medicine*, 18(6), 2322.

Choi PH, et al. (2026) Distinct ERK and PI3K dependencies mediate a heterogeneous response to RAS(ON) inhibition in KRAS-mutant colorectal cancer. *Cell reports*, 45(7), 117559.

Tolotto V, et al. (2026) Class IIa HDACs forced degradation allows resensitization of oxaliplatin-resistant FBXW7-mutated colorectal cancer. *Molecular oncology*, 20(3), 637.

Kanemura H, et al. (2026) Constitutive EGFR Activation Induced by PTPRR Downregulation Confers Resistance to KRAS Inhibitors. *Cancer research communications*, 6(4), 728.

Maiuthed A, et al. (2026) Cytoplasmic p21 promotes stemness of colon cancer cells via activation of the NF- κ B pathway. *Molecular oncology*, 20(4), 1022.

Yuan T, et al. (2026) USP10-mediated deubiquitination and activation of KRAS mutants promotes colorectal cancer via a novel USP10/KRAS positive feedback circuit. *Acta pharmaceutica Sinica. B*, 16(1), 322.

Kehusmaa A, et al. (2026) Tumor Invasive Border Index (TIBI) in colorectal cancer: linking infiltrative morphology to molecular insights. *The Journal of pathology*, 270(1), 114.

He D, et al. (2026) Study of the blood-brain barrier-penetrating KRAS G12C inhibitor JMKX1899 in KRAS G12C-mutated NSCLC with brain metastases. *Journal of the National Cancer Center*, 6(3), 286.

Theardy MS, et al. (2025) Therapeutic targeting of syndecan-1 axis overcomes acquired resistance to KRAS-targeted therapy in gastrointestinal cancers. *Cell reports. Medicine*, 6(8), 102253.

Jameson NM, et al. (2025) The Selective WEE1 Inhibitor Azenosertib Shows Synergistic Antitumor Activity with KRASG12C Inhibitors in Preclinical Models. *Cancer research communications*, 5(2), 240.

Martinez-Martinez D, et al. (2025) Chemotherapy modulation by a cancer-associated microbiota metabolite. *Cell systems*, 16(9), 101397.

Wang P, et al. (2025) Glecirasib, a Potent and Selective Covalent KRAS G12C Inhibitor Exhibiting Synergism with Cetuximab or SHP2 Inhibitor JAB-3312. *Cancer research communications*, 5(5), 792.

Pacini C, et al. (2024) A comprehensive clinically informed map of dependencies in cancer cells and framework for target prioritization. *Cancer cell*, 42(2), 301.

Edelmann M, et al. (2024) Tumor Vessel Normalization via PFKFB3 Inhibition Alleviates Hypoxia and Increases Tumor Necrosis in Rectal Cancer upon Radiotherapy. *Cancer research communications*, 4(8), 2008.

Kong Q, et al. (2023) Alternative splicing of GSDMB modulates killer lymphocyte-triggered pyroptosis. *Science immunology*, 8(82), eadg3196.

Hondo N, et al. (2023) MEK inhibitor and anti-EGFR antibody overcome sotorasib resistance signals and enhance its antitumor effect in colorectal cancer cells. *Cancer letters*, 567, 216264.

Weng W, et al. (2023) AMT-562, a Novel HER3-targeting Antibody-Drug Conjugate, Demonstrates a Potential to Broaden Therapeutic Opportunities for HER3-expressing Tumors. *Molecular cancer therapeutics*, 22(9), 1013.